Clinical trial of ilidar; a new dibenzazepine adrenergic blocking drug, in the treatment of peripheral vascular diseases and miscellaneous complaints.

Ilidar, a new adrenergic blocking drug, has been administered to 116 patients; follow-up was adequate on 86. The drug was highly effective in patients with predominantly vasospastic disorders and in patients with postphlebetic syndrome, and moderately effective in patients with thromboangiitis and arteriosclerosis. Most patients could tolerate 50 to 75 mg. three to four times a day. Side effects were principally those to be expected from the moderate postural hypotension associated with effective sympathetic blockade, namely, weakness, dizziness, nausea. T HIS paper reports the results of the initial clinical trial of Ilidar, a new adrenergic blocking drug. This drug, originally designated as Ro 2-3248, is one of a new group of dibenzazepine derivatives first described by Wenner.1 Many of these, the most potent being Ilidar, were shown to be epinephrine antagonists by Randall and Smith.2 Moore, Richardson and Green3 found Ilidar to be a prompt, moderately long acting vasodila-tor when injected intra-arterially in the nor